DCPXF:OTC-DCPXF (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.01

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

+0.23 (+0.14%)

USD 70.78B
MKKGY Merck KGaA ADR

+0.40 (+1.22%)

USD 70.78B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 41.23B
HLNCF Haleon plc

-0.08 (-2.02%)

USD 38.40B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 14.78B
SGIOF Shionogi & Co. Ltd

N/A

USD 14.21B
SGIOY Shionogi & Co Ltd ADR

+0.03 (+0.25%)

USD 13.35B
ESALF Eisai Co. Ltd

+1.55 (+3.68%)

USD 11.50B
ESAIY Eisai Co. Ltd.

+0.09 (+0.86%)

USD 10.98B
IPSEF Ipsen S.A

N/A

USD 9.73B

ETFs Containing DCPXF

MINF:CA Middlefield Sustainable I.. 5.86 % 0.00 %

+0.12 (+1.31%)

CAD 0.03B
AMUB UBS AG London Branch ELKS.. 0.00 % 0.00 %

+0.20 (+1.31%)

USD 0.08B
CDZ:CA iShares S&P/TSX Canadian .. 0.00 % 0.66 %

+0.14 (+1.31%)

CAD 0.86B
MLPB UBS AG London Branch ELKS.. 0.00 % 0.00 %

+0.24 (+1.31%)

USD 0.24B
XUT:CA iShares S&P/TSX Capped Ut.. 0.00 % 0.62 %

+0.30 (+1.31%)

CAD 0.32B
ZUT:CA BMO Equal Weight Utilitie.. 0.00 % 0.60 %

+0.25 (+1.31%)

CAD 0.41B
MLPR ETRACS Quarterly Pay 1.5X.. 0.00 % 0.00 %

+0.94 (+1.31%)

USD 0.05B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike